Related references
Note: Only part of the references are listed.Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks et al.
NATURE (2022)
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Deborah Plana et al.
CANCER DISCOVERY (2022)
Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma
Nicole L. Michmerhuizen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2022)
Genome-wide identification and analysis of prognostic features in human cancers
Joan C. Smith et al.
CELL REPORTS (2022)
Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity
Kuoyuan Cheng et al.
SCIENCE ADVANCES (2021)
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2020)
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa et al.
CANCER DISCOVERY (2020)
Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Benjamin D. Hopkins et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design
Angel Leon-Buitimea et al.
FRONTIERS IN MICROBIOLOGY (2020)
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Andreas Schneeweiss et al.
BREAST (2020)
Therapeutic development and current uses of BCL-2 inhibition
Andrew W. Roberts
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets
Arnaud Amzallag et al.
BMC BIOINFORMATICS (2019)
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Avinash Das Sahu et al.
MOLECULAR SYSTEMS BIOLOGY (2019)
Network-based prediction of drug combinations
Feixiong Cheng et al.
NATURE COMMUNICATIONS (2019)
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
Fiona M. Behan et al.
NATURE (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
Gabriele Picco et al.
NATURE COMMUNICATIONS (2019)
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
Michael P. Menden et al.
NATURE COMMUNICATIONS (2019)
Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival
Nishanth Ulhas Nair et al.
SCIENTIFIC REPORTS (2019)
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Mario Niepel et al.
CELL SYSTEMS (2019)
RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer
Annapurna Pranatharthi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines
Asmund Flobak et al.
SCIENTIFIC DATA (2019)
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Keelan Z. Guiley et al.
SCIENCE (2019)
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
Joshua M. Dempster et al.
NATURE COMMUNICATIONS (2019)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Mapping the Genetic Landscape of Human Cells
Max A. Horlbeck et al.
CELL (2018)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
Predicting perturbation patterns from the topology of biological networks
Marc Santolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Harnessing synthetic lethality to predict the response to cancer treatment
Joo Sang Lee et al.
NATURE COMMUNICATIONS (2018)
Differential Effector Engagement by Oncogenic KRAS
Tina L. Yuan et al.
CELL REPORTS (2018)
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
Oleksii S. Rukhlenko et al.
CELL SYSTEMS (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
Priya K. Gopalan et al.
Oncotarget (2018)
Synthetic Lethality and Cancer - Penetrance as the Major Barrier
Colm J. Ryan et al.
TRENDS IN CANCER (2018)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
J. Molina-Cerrillo et al.
CANCER TREATMENT REVIEWS (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity
Susan L. Holbeck et al.
CANCER RESEARCH (2017)
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
Thomas Horn et al.
CANCER RESEARCH (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Jennifer O'Neil et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy
Rohith Srivas et al.
MOLECULAR CELL (2016)
A global genetic interaction network maps a wiring diagram of cellular function
Michael Costanzo et al.
SCIENCE (2016)
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
Carlotta Costa et al.
CANCER CELL (2015)
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Kelly M. Zullo et al.
CLINICAL CANCER RESEARCH (2015)
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
Remi Buisson et al.
MOLECULAR CELL (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A. Friedman et al.
PLOS ONE (2015)
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Brinton Seashore-Ludlow et al.
CANCER DISCOVERY (2015)
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Brinda Alagesan et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
Pasi A. Jaenne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer
Hyun Seok Kim et al.
CELL (2013)
CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells
Svetlana Grabauskiene et al.
LUNG CANCER (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Matthew A. Held et al.
CANCER DISCOVERY (2013)
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Amy D. Guertin et al.
CANCER CELL INTERNATIONAL (2012)
Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors
Joannah N'gompaza-Diarra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
Beat Nyfeler et al.
PLOS ONE (2012)
TRIAL WATCH Phase III and submission failures: 2007-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Roi Avraham et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Use of Antifungal Combination Therapy: Agents, Order, and Timing
Melissa D. Johnson et al.
CURRENT FUNGAL INFECTION REPORTS (2010)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1
Y Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
